Conditions: Esophageal Carcinoma
Keywords: Esophageal Carcinoma Cisplatin Irinotecan Radiation Therapy 02-045
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 61
Healthy volunteers: no

Brief summary:
Patients with surgically resectable T1N1M0 or T2-4N any M0 esophageal carcinoma will receive six weeks of induction chemotherapy with weekly irinotecan and cisplatin given weeks 1, 2, 4 and 5. Patients will then receive weekly irinotecan, cisplatin, and concurrent radiotherapy with chemotherapy given once weekly, weeks 8,9,11 and 12 during the six weeks of radiotherapy. Patients will be referred for surgery 4-8 weeks after completion of chemoradiotherapy.

Detailed description:

Arms:
arm 1: External Beam Radiation Therapy, Cisplatin, Irinotecan

Interventions: intervention 1: Cisplatin intervention 2: Irinotecan intervention 3: External Beam Radiation Therapy
Intervention descriptions: intervention 1: pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12 intervention 2: Irinotecan will be given 65 mg/m2 intervention 3: will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.

Protocol document: